Gastric cancer · 3 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
DOS Variant #01 Partial | — | R 2 888 | 21d | — | — | ~3 | ~R 8 664 indirect | — |
ECF Variant #01 | — | R 2 442 | 21d | — | 48.0 mo | 9 | R 21 982 PFS proxy | 2 |
No neoadjuvant therapy Partial | — | — | — | — | — | — | — | 2 |
3 of 3 regimens shown